Research Study: MGH HALT

Valvular Disease (Heart Valve Disease)
Study Sponsor:
Massachusetts General Hospital
Study Investigator:
Joao Cavalcante, MD
Study Contact:

Every research study comes with its own unique risks and benefits; the study team will assess whether you’re an eligible candidate and ensure you’re provided with all the information you need to decide if participating is right for you.

About this Study:

The purposes of the HALT Biomarkers study are to identify a panel of circulating proteins that discriminates between patients with and without Hypo-Attenuated Leaflet Thickening (HALT) and can be used to supplement the diagnosis of HALT; to characterize changes in circulating proteins after treatment of HALT with systemic anticoagulation; and to identify circulating proteins that predict the occurrence of HALT.

Eligibility Criteria:

  • Age > 65 years
  • Subject with severe native AS or severe bioprosthetic valve degeneration
  • Subject undergoing transfemoral TAVR using a Medtronic Evolut R, Evolut Pro or Evolut Pro+ transcatheter heart valve

Get More Information At